Intermediate vaccine responses would be expected for patients with anti-cytotoxic T-lymphocyte antigen-4 therapy, hematologic cancer, and human immunodeficiency virus infection with low CD4 counts. Here, CD4 is linked to hematopoietic and lymphoid cell neoplasm.